Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $28.00. The ...

Shareholders have already approved a pay increase for British American Tobacco chief executive Tadeu Marroco. He could ...

Peter Kotlár has long promoted fringe theories about mRNA vaccines, claiming they "cause the human body to produce toxins." ...

Three galleries from Romania and the Republic of Moldova will take part in the contemporary art fair Art Brussels 2025, which ...

Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday. The news sent company shares ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...